Levetiracetam Tablet
Product Images NDC 50090-7820

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50090-7820). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907820)

Levetiracetam 500 mg oral tablets packaging label from A-S Medication Solutions. The label shows the product name, strength, dosage form, storage instructions (68 to 77 degrees F), quantity of 120 tablets, and a QR code for dosage and packaging information. The label also includes an NDC number 50090-7820-0 and mentions the manufacturer location in Libertyville, Illinois.*

FDA Label Image

Structure Formula (Levetiracetam Tablets 1)

Chemical structure of levetiracetam, showing its molecular skeleton including a pyrrolidone ring and associated functional groups.*

FDA Label Image

Figure1 (Levetiracetam Tablets 2)

A bar chart comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The y-axis shows the percentage of patients from 0% to 45%. The bars show 7.4% for Placebo, 37.1% for Levetiracetam 1000 mg/day, and 39.6% for Levetiracetam 3000 mg/day, with asterisks indicating statistical significance for the Levetiracetam groups.*

FDA Label Image

Figure2 (Levetiracetam Tablets 3)

A bar chart comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day, with percentages displayed on the vertical axis and patient groups labeled on the horizontal axis. The chart shows increasing percentages from placebo to higher doses of Levetiracetam.*

FDA Label Image

Figure3 (Levetiracetam Tablets 4)

A bar graph comparing the percentage of patients between two groups: Placebo and Levetiracetam 3000 mg/day. The Placebo group (N=104) shows 14.4% patients, and the Levetiracetam group (N=180) shows 39.4% patients. The graph's y-axis represents the percentage of patients from 0% to 45%.*

FDA Label Image

Figure4 (Levetiracetam Tablets 5)

A bar chart comparing the percentage of patients between two groups: Placebo (N=97) and Levetiracetam (N=101). The chart shows 19.6% of patients in the Placebo group and 44.6% in the Levetiracetam group, with a star indicating statistical significance for the Levetiracetam group.*

FDA Label Image

Figure5 (Levetiracetam Tablets 6)

Bar chart comparing the percentage of patients between Placebo and Levetiracetam groups. The chart shows about 19.6% of patients in the Placebo group (N=51) and 43.1% in the Levetiracetam group (N=58). The y-axis represents the percentage of patients, and the x-axis shows the two groups.*

FDA Label Image

Figure6 (Levetiracetam Tablets 7)

A bar graph comparing the percentage of patients in two groups: Placebo (N=84) and Levetiracetam (N=79). The y-axis represents the percentage of patients from 0% to 100%. The Placebo group shows 45.2%, while the Levetiracetam group shows 72.2%, marked with an asterisk.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.